RxDoctor Payments Data

Rebecca Lillis, MD

Infectious Disease · New Orleans, LANPI 1760481592

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Cepheid at 43.5% of the total. Among infectious disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,969in general payments, 2019–2025

Across 39 payments — averaging $1537.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cepheid$26K
  • Roche Molecular Systems, Inc.$13K
  • Roche Diagnostics International Ltd$6K
  • Ortho-clinical Diagnostics, Inc.$5K
  • Biomerieux Inc$4K
  • Abbott$3K
  • plus $3K from 3 others
$2,678,039in research payments, 2019–2025

Across 190 payments — averaging $14,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Molecular Systems, Inc.$759K
  • BD$536K
  • Biofire Diagnostics, LLC$479K
  • Visby Medical, Inc.$413K
  • Cepheid$201K
  • Ortho-clinical Diagnostics, Inc.$137K
  • plus $153K from 3 others

What the payments were for

  • Consulting fees$22,89138%
  • Speaking & faculty fees$30,99752%
  • Travel & lodging$5,6609%
  • Food & beverage$4211%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,969 in reported general payments places this provider in the 95th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,209
Medicare patients
12
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →